EN DE
Watch Idorsia Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Idorsia Ltd (IDIA) fair value: what the stock is really worth

As of Nov 11, 2026: fair value (intrinsic value) of Idorsia Ltd stock CHF 3.59, price CHF 4.01, that is 10.6% below the price, quality 37 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CH · ISIN CH0363463438

IL Idorsia Ltd logo Thin data Nov 10, 2026

Idorsia Ltd

IDIA · SW
Expensive, weak quality

Our calculation puts a fair price 11% below what the stock costs today.

Last quarter vs. a year ago: revenue +49%, profit +77%.
Mixed Growth (revenue 5y +25.2 %/yr in CHF)
Negative equity (buybacks among others)
Mixed vs. peers (3/7)
Fair value CHF 3.59 · Overvalued
Quality 37/100
Loss-making · -128.8% net margin (TTM)
Negative free cash flow
Narrow moat 12/100 · thin data
Thin data
Estimate
Watch Idorsia Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

CHF 23.24 CHF 0.6325 Fair Value CHF 3.59 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range CHF 0.6325 – CHF 23.24 · fair‑value band CHF 2.69 – CHF 4.49 · the CHF 4.01 price screens above the CHF 3.59 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Idorsia in your weekly email

Every Wednesday you see whether Idorsia is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada.

Show moreShow less

The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia.

The company's product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial to treat fabry disease; Daridorexant, a dual orexin receptor antagonist, which is in phase 2 clinical trial for the treatment of pediatric insomnia; IDOR-1117-2520, a CCR6 receptor antagonist which is in phase 1 clinical program to treat psoriasis; ACT-777991, a CXCR3 antagonist, which is in preclinical trial to treat vitiligo; and ACT-1004-1239, an ACKR3 receptor antagonist which is preclinical trial for the treatment of progressive multiple sclerosis.

It also develops ACT-1016-0707, a LPA 1 receptor antagonist to treat immune-mediated and fibrosis related disorders; IDOR-1141-8472, an orexin 2 receptor agonist to treat orexin-related CNS disorders; and IDOR-1126-6421 to treat organ injury.

The company holds a license agreement with Neuro to develop and commercialize clazosentan; collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; and collaboration with Viatris Inc. to develop and commercialize selatogrel and cenerimod.

Idorsia Ltd was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Stock analysis

Idorsia Ltd (IDIA) currently trades at CHF 4.01, while our estimate is CHF 3.59, 11% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: CHF 2.69 (bear) to CHF 4.49 (bull), the price of CHF 4.01 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Idorsia Ltd reported revenue of CHF 221M in FY2025 versus CHF 35.3M in FY2021, a compound +58.1%/yr. Reported net income was −CHF 112M in FY2025.

Key figures

Market cap CHF 1.0B Small · P/S ratio 4.97 · EPS (TTM) CHF −1.15 · Net margin −129% · Return on equity −6,461% · Return on assets (EBIT) −51.0% (5-year average) · Operating margin −57.8% · Revenue (TTM) CHF 220M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 42% below its 52-week high and 37% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −11%, IDIA screens richer than that median.

Fair Value

Bear CHF 2.69 Fair Value CHF 3.59 Bull CHF 4.49
Price CHF 4.01 · Downside -10.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 37/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 25
How much profit the company makes from its sales and capital
Quality Growth 100
Are margins and returns getting better?
Cashflow 19
Do the profits arrive as real cash?
Financial strength 21
Debt, balance sheet and risk of trouble
Investment 88
Does it invest with discipline instead of growing at any price?
Low Volatility 5
How calm the share price moves, does not count
Price momentum 36
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 46
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+96.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.2%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−572.2% (2020) → −59.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

IDIA screens overvalued: fair value 11% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Idorsia Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 37 · Below median
Fair Value upside −10.6% · Top 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −24.0% · Below median
Net margin (12 months) −128.8% · Bottom 25%
Operating margin (12 months) −57.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 49.3% · Top 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 4.67× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)19 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $959.41 $1,275 +33% vs IDIA
Vertex Pharmaceuticals Incorporated VRTX $547.03 $602.68 +10% vs IDIA
Samsung Biologics Co 207940 1,430,000 KRW 1,573,000 KRW +10% vs IDIA
Genmab A/S GMAB kr 3,561 kr 3,880 +9% vs IDIA
argenx SE ARGX $977.58 $908.40 −7% vs IDIA
CSL Limited CSL A$204.54 A$181.40 −11% vs IDIA
Moderna, Inc MRNA $248.69 $158.70 −36% vs IDIA
BeOne Medicines AG 6160 HK$251.80 HK$152.80 −39% vs IDIA
Celltrion, Inc 068270 207,000 KRW 74,945 KRW −64% vs IDIA
Royalty Pharma plc RPRX $70.01 $19.01 −73% vs IDIA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Idorsia Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Idorsia Ltd Fair Value". https://www.fairvalue-calculator.com/stock/IDIA

Frequently asked questions

Is Idorsia Ltd (IDIA) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is CHF 3.59 versus a price of CHF 4.01, about 11% lower (overvalued).
What is the fair value of IDIA?
Our estimate for Idorsia Ltd is CHF 3.59 (as of Nov 10, 2026), built from audited fundamentals. The current price: CHF 4.01.
What is the quality score of IDIA?
Idorsia Ltd has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Idorsia Ltd (IDIA)?
Our calculated price target is the estimate of CHF 3.59 (as of Nov 10, 2026). Cautious scenario CHF 2.69, optimistic scenario CHF 4.49. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Idorsia Ltd stock forecast for 2026?
Our estimate puts fair value at CHF 3.59, about 11% lower versus a price of CHF 4.01 (overvalued). Cautious scenario CHF 2.69, optimistic scenario CHF 4.49. The calculation is refreshed regularly with new filings.
What is the revenue of Idorsia Ltd (IDIA)?
Idorsia Ltd reported trailing-twelve-month revenue of about CHF 220M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Idorsia Ltd (IDIA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Idorsia Ltd it is CHF 3.59 per share (as of Nov 10, 2026), against a price of CHF 4.01.
Is Idorsia Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, IDIA trades above its calculated fair value: price CHF 4.01, fair value CHF 3.59, a gap of about −11% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IDIA?
No. The price is what the market pays today (CHF 4.01); the fair value is what the company's own numbers justify (CHF 3.59). For Idorsia Ltd the two are CHF 0.4240 per share apart. That gap is exactly why we show both numbers side by side.
How much is Idorsia Ltd worth?
The market values Idorsia Ltd at about CHF 1.0B (market capitalisation, as of Nov 10, 2026). Per share that is CHF 4.01; our models calculate a fair value of CHF 3.59 per share.
What do the bullish and bearish scenarios say about IDIA?
Our models span a range for Idorsia Ltd: cautious scenario CHF 2.69, base CHF 3.59, optimistic CHF 4.49 per share (as of Nov 10, 2026, price CHF 4.01). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Idorsia Ltd (IDIA)?
Balance-sheet figures for Idorsia Ltd (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is IDIA from its 52-week high?
Idorsia Ltd trades at CHF 4.01, about 42% below its 52-week high of CHF 6.89 and 37% above the low of CHF 2.93 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 3.59 is for.
Which stocks are comparable to Idorsia Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Idorsia Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price CHF 4.01, calculated fair value CHF 3.59 (−11%), Quality Score 37/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Idorsia Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Idorsia Ltd (IDIA)?
The closing price on Nov 11, 2026 was CHF 4.01. Our estimate is CHF 3.59, about 11% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Idorsia Ltd right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Idorsia Ltd

How large is the market capitalisation of Idorsia Ltd (IDIA)?
The market capitalisation of Idorsia Ltd is CHF 1.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Idorsia Ltd (IDIA)?
The price-to-sales ratio of Idorsia Ltd is 4.97 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Idorsia Ltd (IDIA)?
Earnings per share at Idorsia Ltd are CHF −1.15. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Idorsia Ltd (IDIA)?
The net margin of Idorsia Ltd is −129% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Idorsia Ltd (IDIA)?
The return on equity (ROE) of Idorsia Ltd is −6,461% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Idorsia Ltd (IDIA)?
On an EBIT basis the return on assets of Idorsia Ltd is −51.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Idorsia Ltd (IDIA)?
The operating margin of Idorsia Ltd is −57.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Idorsia Ltd (IDIA)?
Revenue at Idorsia Ltd is growing +49.3% versus a year earlier (3y avg +31.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Idorsia Ltd (IDIA)?
Earnings per share at Idorsia Ltd are growing +76.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Idorsia Ltd (IDIA) generate?
The free cash flow of Idorsia Ltd is −CHF 167M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Idorsia Ltd (IDIA) carry?
The net debt of Idorsia Ltd is CHF 1.2B (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Idorsia Ltd in the live analysis

One click puts Idorsia Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.